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Abstract
In this case presentation, we describe the challenges of performing magnetic resonance-guided
radiation therapy (MRgRT) with plan adaptation in a patient with advanced endometriosis, in
whom several prior therapeutic attempts were unsuccessful and extensive pelvic irradiation
was regarded as being too toxic. Treatment was delivered in two sessions, first for the
seemingly only active right ovary, and at a later stage for the left ovary. Some logistical
problems were encountered during the preparation of the first treatment, which were
subsequently optimized for the second treatment by using transvaginal ultrasound to
determine the optimum time point for simulation and delivery. Using breath-hold gated
delivery and plan adaptation, radiation dose to the bowel could be minimized, resulting in good
tolerance of treatment. Because of the need to simulate and deliver in a brief optimal time span
for visibility of the follicles in the ovaries, a single fraction dose of 8 Gy was used in our patient.
Hormonal outcome after her second treatment is still pending.
In conclusion, MRgRT with plan adaptation is feasible for the occasional patient with refractory
endometriosis. Simulation and delivery needs to be synchronized with the menstrual cycle,
ensuring that the Graafian follicles allow the ovaries to be visible on magnetic resonance
imaging (MRI). Because the ovaries are only visible on T2-weighted MRI for a very brief period
of time, we suggest that it is preferable to use single fraction radiotherapy with a brief interval
between simulation imaging and delivery.
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Introduction
Endometriosis constitutes a benign gynecological condition that is characterized by the
presence of ectopic endometrial-like tissues. Endometriosis is a chronic inflammatory disorder
that can significantly impact upon the quality of life with symptoms ranging from
dysmenorrhea to pelvic or abdominal bowel symptoms, and in severe cases even obstruction or
perforation [1]. Although pain medication, hormonal therapy, or surgery form the mainstay of
treatment for symptomatic patients, radiotherapy, usually in the form of extensive pelvic
irradiation, has been applied in exceptional cases with refractory disease [2-3]. In this case
presentation, we describe the challenges of performing magnetic resonance-guided radiation
therapy (MRgRT) in a patient with advanced endometriosis, in whom several prior therapeutic
attempts were unsuccessful and extensive pelvic irradiation was regarded as being too toxic.
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Case Presentation
A 44-year-old woman with an extensive history of advanced and refractory endometriosis
presented with abdominal complaints associated with a pseudo-obstruction bowel syndrome.
She had previously undergone multiple abdominal surgeries, including a subtotal colectomy.
She did not respond to ovarian suppression with gonadotropin-releasing hormone agonist, and
a recent embolization of both ovarian arteries only achieved a partial and temporal hormonal
response. Repeated post-embolization transvaginal ultrasound investigations could only
discriminate the right ovary; the atrophic left ovary could not be visualized. Surgical
ovariectomy was considered to be high-risk because of extensive abdominal and pelvic
adhesions on a diagnostic magnetic resonance imaging (MRI). She subsequently was referred by
her treating gynecologist for radiation to the right ovary in order to achieve a postmenopausal
hormonal status. Because the patient suffered from chronic and severe bowel complaints with a
need for total parenteral nutrition, extensive pelvis radiation, a historical method for ovarian
ablation, was considered contraindicated. MR-guided radiotherapy, a recently introduced
advanced technique, was preferred in order to optimally spare the surrounding bowel and
selectively treat the right ovary.
In preparation of MRgRT, on the day of the initial consultation, a simulation (SIM) MR scan was
performed on MRIdian (Viewray Inc., Mountain View, US). The SIM MR scan was acquired in
shallow breath-hold in order to restrict respiratory artifacts. The MRIdian uses a 0.35 Tesla
magnetic field with a balanced steady state free precession (bSSFP) sequence. In this sequence
on the MRIdian, there is heavy T2 weighting, hence the fluid and the ovarian follicles are
bright. However, as this acquired SIM MR scan did not take the phase in the menstrual cycle
into account, none of the ovaries were clearly detectable. This was confirmed by an experienced
radiologist specialized in abdominal MRI who advised to perform a diagnostic MR scan first.
This scan was performed three weeks later and showed multiple follicles in the right ovary,
with only a small cyst at the location of the left ovary (Figure 1).
FIGURE 1: Coronal images from the diagnostic magnetic
resonance imaging (MRI) scan
Coronal T2-weighted images from the diagnostic MR scan showing the right ovary with three
small follicles (thick arrow) with a maximum diameter of 15 mm. The left ovary is not clearly
recognizable, but a small cyst is visible with a maximum diameter of 8 mm at the position of the
ovary (thin arrow).
With the duration of the menstrual cycle in mind, the SIM MR scan was repeated one month
later showing a comparable image of the ovaries as on the diagnostic MRI. This SIM MR was
used for the generation of a baseline plan, prescribing 8 Gy in a single fraction to the right
ovary. Several days after the SIM MR, the patient returned for the scheduled treatment.
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Unfortunately, because she appeared to be in a postovulatory phase of her menstrual cycle, the
right ovary could not be seen on the pretreatment MR scan. Two more attempts in the weeks
thereafter had to be performed before the right ovary was visible, and treatment could actually
be delivered. Plan re-optimization was useful, because both the position and volume of the
right ovary were different on the SIM MR and the pretreatment MR (Figure 2). Treatment was
delivered in shallow inspiration breath-hold with a 3 mm gating boundary between the right
ovary and the planning target volume (PTV).
FIGURE 2: Simulation scan versus pretreatment scan
A coronal and axial view of the simulation scans is displayed on the left panels. On the right, a
coronal and axial view of radiotherapy treatment fraction is seen.
Green = the right ovary. Red = treatment boundary.
The patient reported mild symptoms of an inflated belly and some fatigue for which no
intervention was required in the first days following treatment, both scored as grade 1 toxicity
(CTCAE criteria v. 4.3). She experienced neither nausea nor diarrhea. Hormonal assessment at
four months follow-up revealed a serum estradiol (E2) of 40 pmol/L and serum follicle
stimulating hormone (FSH) level of 70 U/L, indicating that she biochemically had reached a
postmenopausal status. In addition to the hot flushes she experienced, the patient also
reported having fewer abdominal complaints. Unfortunately, at six months follow-up, the
patient appeared to have regained a biochemical premenopausal status. In addition, this was
confirmed by a transvaginal ultrasound that showed follicles, this time in an apparently active
left ovary. As a result of this finding, the patient was referred for local treatment by
radiotherapy, now for her left ovary.
Having learned from the first procedure, this time the MRgRT was synchronized with her
menstrual cycle by performing weekly transvaginal ultrasound in order to determine the
appropriate treatment window. As soon as the follicle was visible in the left ovary, the patient
was seen at our department with immediate MR simulation. After quick planning, the patient
was treated within 24 hours of the SIM MR scan with a single dose of 8 Gy. Similar to the first
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treatment, the patient noticed mild abdominal complaints and fatigue in the first days
following the second treatment. Toxicity did not impact upon her daily activities and was
therefore scored as grade 1. At one month after treatment, she reported that her bowel
symptoms were better than in previous years. She had even been able to discontinue total
parenteral nutrition. The biochemical results after radiotherapy on the left ovary are pending.
Discussion
This case report describes an uncommon indication for radiotherapy with the goal to obtain
ovarian ablation in a patient with refractory and advanced endometriosis. Given the extensive
bowel complications in this patient, neither surgical ovariectomy nor extensive pelvic radiation
was considered feasible. It was contemplated that MR-guided focal radiotherapy directed
towards the remaining active right ovary might be beneficial in order to diminish potential
gastro-intestinal side effects. One main difference between conventional radiotherapy (such as
e.g., extensive pelvic irradiation) and MRgRT is that setup and radiation delivery is delivered to
a specific target rather than a region. Contrary to conventional radiotherapy, this necessitates
that the ovary is discernible on SIM and pretreatment MR scans.
Diagnostic MR imaging of the normal ovaries is usually performed using T2-weighted imaging,
which makes the bSSFP sequence of the MRIdian suitable for visualizing the ovaries. During the
menstrual cycle, the Graafian follicles can be seen as bright cysts within the ovarian stroma, and
this pre-ovulatory phase is ideal for imaging. Both simulation and MR-guided delivery,
therefore, have to take place in the last days of this relatively short time slot. During the first
treatment fraction, we used ‘trial and error’ and the irregular cycle of our patient necessitated
several visits. In anticipation of the second treatment, simulation and delivery were
synchronized with her menstrual cycle by performing sequential transvaginal ultrasound
investigations. Once the follicles were visible on this imaging, simulation and delivery took
place within 24 hours. For the same reason, we used single fraction radiotherapy, rather than a
more prolonged fractionation scheme. Clinical experience of ovarian ablative radiotherapy is
mostly derived from older literature in breast cancer patients and has only been reported in
case reports for refractory endometriosis [2-3]. While radiotherapy for endometriosis is most
commonly delivered in the form of extensive pelvic irradiation in 15-20 Gy in 10 fractions, the
literature on hormonal castration in breast cancer patients describes a wider range of
fractionation schemes, including the use of single-fraction irradiation. Because the most
frequently applied radiation scheme in the literature is 15 Gy in 5 fractions [4], we selected a
single fraction dose of 8 Gy which has a comparable biological equivalent dose for an α/β of 3
and slightly lower than that for an α/β of 10.
From a practical standpoint, we performed a scan during the shallow breath-hold and with a
full bladder to optimize visibility of the ovary, minimize target (and bowel) mobility, and enable
bowel spacing. Plan adaptation was used to generate a conformal as possible dose distribution.
The cumulative dose distribution from both fractions can be seen in Figure 3, which clearly
illustrates the resulting relative sparing of the surrounding bowel, especially when compared
with conventional extensive pelvis irradiation. Despite two treatments with 8 Gy, the acute
toxicity has been minimal with temporary bowel symptoms and some fatigue. The results of
hormonal outcome in our patient are pending.
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FIGURE 3: The cumulative dose distribution
A coronal and axial view of dose accumulation of both treatments projected on the first
simulation magnetic resonance (SIM MR) scan.
Blue color wash = 4Gy. Inner red color wash = 8 Gy.
Conclusions
MRgRT with plan adaptation is feasible for the occasional patient with refractory
endometriosis. Simulation and delivery needs to be synchronized with the menstrual cycle,
ensuring that the Graafian follicles allow the ovaries to be visible on MRI. Because the ovaries
are only visible on T2-weighted MRI for a very brief period of time, we suggest that it is
preferable to use single fraction radiotherapy with a brief interval between simulation imaging
and delivery.
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